HK Stock Market Move | HENLIUS (02696) surged over 7% in the afternoon, with data on HLX43 for thymic squamous cell carcinoma and research results related to H drug for lung cancer set to be unveiled soon.

HENLIUS (02696) rose over 7% in the afternoon, increasing by 7.64% to report HKD 59.9, with a trading volume of HKD 31.025 million. In news, the 2026 World Conference on Lung Cancer (WCLC) will be held from September 12 to 15 in Seoul, South Korea. HENLIUS will unveil several latest research findings on its innovative products at the conference, covering Phase I study data for the PD-L1 ADC HLX43 in thymic squamous carcinoma, as well as seven research data points for the anti-PD-1 monoclonal antibody Hansizhuang in the fields of extensive-stage small cell lung cancer, limited-stage small cell lung cancer, and large cell neuroendocrine carcinoma. Additionally, HENLIUS's self-developed innovative PD-L1 antibody-drug conjugate (ADC) injection HLX43, in combination with bevacizumab and combined or not combined with chemotherapy for the treatment of advanced/metastatic solid tumors, has received approval for clinical trial application from the National Medical Products Administration (NMPA). According to a simultaneous announcement from Shanghai Fosun Pharmaceutical, as of July 31, 2026, there are no similar combination therapy regimens approved for marketing worldwide.